Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Jan 6 2025

Full Issue

Trump's FDA Transition Team Staffs Up As Commissioner Pick Awaits Approval

Meanwhile, newly installed Senate Majority Leader John Thune signals the president-elect's Cabinet nominees might not cruise to confirmation when hearings begin. Also, U.S. ethics director David Huitema has begun the standard practice of looking into conflicts of interest for incoming officials.

Stat: Trump FDA Transition Team Takes Shape: Zeta, Traficant 

The Trump administration’s Food and Drug Administration transition team is taking shape, with a former adviser to ex-Commissioner Stephen Hahn and a top executive of a communications firm that has worked with Trump’s FDA commissioner pick Marty Makary. The team is in conversations with a top Capitol Hill aide about a key role at the agency. (Zhang, 1/3)

Boston Herald: Senate Majority Leader Warns No 'Clarity' On Trump Cabinet Picks As Hearings Due To Begin

On Friday, when the U.S. Congress began its 119th session, new Senate Majority Leader John Thune said the upper chamber would work swiftly to “ensure President Trump has his team in place to secure our border, protect our homeland, and provide for our nation’s defense.” But by Sunday the South Dakota Republican was tapping the brakes as he made the talk show rounds, explaining that Trump’s top picks are going to have some “hard questions” to answer before they are confirmed. (Medsger, 1/5)

Reuters: Exclusive: New US Ethics Czar Starts Vetting Incoming Trump Officials 

The top U.S. ethics official charged with preventing government workers' conflicts of interest is about to take the hot seat in Washington, as President-elect Donald Trump's new Cabinet and other appointees declare their financial assets and prepare for their new jobs. "We are in touch with the transition team and working with them," said David Huitema recently when he sat down with Reuters for his first official interview since being sworn in for the job on Dec. 16. Ethics experts say the director of the Office of Government Ethics, or OGE, is in the spotlight during any presidential transition, but Huitema faces special challenges ahead of Trump's second term, evaluating a myriad of business ties for Trump, his family and advisers. Experts pointed to the short, rocky tenure of Walter Shaub, the last person to hold the job when Trump entered the White House. (Timmons and Borter, 1/5)

Marijuana Moment: Former Texas Governor Who Served In Trump's Cabinet Says President-Elect's Health Picks Are A 'Great Gift' For Psychedelics Reform 

Rick Perry, a former governor of Texas who also served in the first Trump administration, says the president-elect’s new choices for key health policy positions are a “great gift” for the psychedelics reform movement, particularly as it concerns access to ibogaine as a treatment option for serious mental health conditions. ... The former Department of Energy (DOE) secretary also sharply criticized the Schedule I status of ibogaine under the Controlled Substances Act (CSA), saying the designation means “it can’t even be used for clinical trials” and “can’t be medically used to see, is there some good that can come out of this?” (Jaeger, 1/3)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF